Absolute changes in LIC values
. | No. Patients (means ± SD) . | . | |
|---|---|---|---|
. | Deferasirox . | Deferoxamine . | |
| No. patients | 268 | 273 | |
| Patients evaluated by biopsy or SQUID | |||
| All LIC values | 268 (-2.4 ± 8.2) | 273 (-2.9 ± 5.4) | |
| LIC below 7 mg Fe/g dw | 83 (4.0 ± 3.8) | 87 (0.13 ± 2.2) | |
| LIC at least 7 mg Fe/g dw | 185 (-5.3 ± 8.0)* | 186 (-4.3 ± 5.8) | |
| Patients evaluated by biopsy only | |||
| All LIC values | 224 (-3.0 ± 8.8) | 230 (-3.2 ± 5.7) | |
| LIC below 7 mg Fe/g dw | 52 (5.6 ± 3.8) | 55 (0.5 ± 2.5) | |
| LIC at least 7 mg Fe/g dw | 172 (-5.6 ± 8.2)* | 175 (-4.4 ± 6.0) | |
| Patients evaluated by SQUID only | |||
| All LIC values | 44 (0.5 ± 2.9) | 43 (-1.1 ± 1.9) | |
| LIC below 7 mg Fe/g dw | 31 (1.4 ± 2.1) | 32 (-0.5 ± 1.3) | |
| LIC at least 7 mg Fe/g dw | 13 (-1.5 ± 3.7) | 11 (-2.9 ± 2.3) | |
. | No. Patients (means ± SD) . | . | |
|---|---|---|---|
. | Deferasirox . | Deferoxamine . | |
| No. patients | 268 | 273 | |
| Patients evaluated by biopsy or SQUID | |||
| All LIC values | 268 (-2.4 ± 8.2) | 273 (-2.9 ± 5.4) | |
| LIC below 7 mg Fe/g dw | 83 (4.0 ± 3.8) | 87 (0.13 ± 2.2) | |
| LIC at least 7 mg Fe/g dw | 185 (-5.3 ± 8.0)* | 186 (-4.3 ± 5.8) | |
| Patients evaluated by biopsy only | |||
| All LIC values | 224 (-3.0 ± 8.8) | 230 (-3.2 ± 5.7) | |
| LIC below 7 mg Fe/g dw | 52 (5.6 ± 3.8) | 55 (0.5 ± 2.5) | |
| LIC at least 7 mg Fe/g dw | 172 (-5.6 ± 8.2)* | 175 (-4.4 ± 6.0) | |
| Patients evaluated by SQUID only | |||
| All LIC values | 44 (0.5 ± 2.9) | 43 (-1.1 ± 1.9) | |
| LIC below 7 mg Fe/g dw | 31 (1.4 ± 2.1) | 32 (-0.5 ± 1.3) | |
| LIC at least 7 mg Fe/g dw | 13 (-1.5 ± 3.7) | 11 (-2.9 ± 2.3) | |
P = .001; deferasirox populations with a statistically significant reduction in LIC from baseline; 1-sample Student t test (1-sided, alpha = 2.5%).